Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Aug 20, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

PRNewsWire • Aug 19, 2026

Here's Why Exelixis (EXEL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 18, 2026

Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky

Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating.

PRNewsWire • Aug 17, 2026

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law.

Business Wire • Aug 16, 2026

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL)

Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell

GlobeNewsWire • Aug 13, 2026

EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)

NEW YORK--(BUSINESS WIRE)--Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The revenue shortfall came alon.

Business Wire • Aug 12, 2026

EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis

Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of EXEL shareholders.

PRNewsWire • Aug 11, 2026

Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)

On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the Company lowered and narrowed that revenue outlook -- and the stock fell.

PRNewsWire • Aug 10, 2026

EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.

Zacks Investment Research • Aug 6, 2026